87 results about "MEZLOCILLIN SODIUM" patented technology

The invention relates to a mezlocillin sodium compound which is determined by adopting X-ray powder diffraction and has characteristic peaks shown in 2theta of 8.9, 15.7, 16.5, 18.9, 19.8, 24.6, 26.4, 27.8, 29.0, 29.7, 31.8, 33.2, 34.7, 36.8, 37.5, 38.9 and 40.1 in a map. The invention also relates to a mezlocillin sodium compound and a medicine composition with a medicine active component of the mezlocillin sodium compound or the mezlocillin sodium compound and sulbactam sodium or tazobactam sodium. The medicine composition is a powder injection of the mezlocillin sodium compound, or a medicine mixture powder injection of the mezlocillin sodium compound and the sulbactam sodium or tazobactam sodium. The mezlocillin sodium compound has the advantages of difficulty in absorbing mixture, good flowability, high dissolving speed, kept extremely high stability, and greatly improved convenience and safety of the mezlocillin sodium.

The invention provides a preparation method of mezlocillin sodium-sulbactam sodium for injection and the freeze-dried powder injection thereof as well as a separating and purifying method of the mezlocillin sodium and sulbactam sodium for injection. By adopting high speed countercurrent chromatography, the invention prepares trichloromethane, methanol and water to form a solvent system with an immobile phase and a mobile phase and separates and purifies mezlocillin sodium and sulbactam sodium to obtain the mezlocillin sodium and sulbactam sodium for injection; the purity of the obtained product can reach more than 99% and the prepared injection has improved stability.

The invention belongs to the technical field of medicine, and discloses a medicinal-composition suspension powder injection taking mezlocillin sodium and sulbactam sodium as active components. The injection comprises 4 parts of mezlocillin sodium, 1 part of sulbactam sodium, 5 to 20 parts of Tween 80, 1 to 10 parts of cholesterol, 0.5 to 15 parts of deoxysodium cholate, and 2 to 30 parts of frozen-dried supporting agent. The invention further discloses novel application of the injection in the preparation of medicaments for preventing postoperative infection of appendicitis.

Disclosed is a process for preparing mezlocillin sodium belonging to compound preparation technical field. By acylation reaction of aminobenzyl triaqua acid with 1-chloroformyl-3-mesyl-2-imidazolidinone, acidizing after an ethyl acetate solvent being added, esterified layer removing, salifying reaction after a sodium salt forming agent being added, and seedout, the mezlocillin sodium is obtained. In the invention, the mixed solvent is adopted and the speed of adding the sodium salt forming agent is adjusted. There is recrystallization buffer, so the crystal grain is big and the purity is high.

The invention discloses a preparation method of mezlocillin sodium solvent crystal, comprising the steps of (1) dissolving crude mezlocillin acid in a reaction solvent A to obtain solution A; (2) dissolving organic salt forming agent in a reaction solvent B to obtain solution B; (3) after adding the solution A into the solution B for sufficient reaction, slowly adding a poor solvent, separating out sodium solvent crystal, filtering, obtain filtrate and filter mass, drying the filter mass; the organic salt forming agent is sodium iso-octoate, ethyl acetoacetate or 2-ethyl sodium hexanoate; the reaction solvent A or B is independently acetone or ethyl acetate; the poor solvent is methanol, ethanol, propanol, isopropanol, aether, isopropyl ether, tetrahydrofuran, ethyl formate orbutyl acetate. The method is simple to operate, and has high stability, large yield, excellent product quality and few impurity contents; the reaction solvents and crystallizing solvent can be recycled, thus having low production cost, high reaction yield, excellent implementing value, and social and economic benefits.

The invention relates to a preparation technique of mezlocillin sodium freeze-dried powder, which comprises the following steps of: (1) mixing and stirring mezlocillin and distilled water; (2) adding saturated sodium bicarbonate solution until the pH value of the reaction liquid reaches 4.5-7.5, and continuing stirring; (3) adding activated carbon, which accounts for 0.3% of the reaction liquid by volume, to the reaction liquid, and stirring to decoloring the reaction liquid; (4) carrying out rough filtration by using filter paper, and carrying out fine filtration on the rough filtration liquid by using a 0.22 mum filter membrane; (5) sublimating water in the fine filtration liquid by freeze-drying; and (6) collecting the material, pulverizing and screening to obtain the mezlocillin sodium aseptic powder. The preparation technique has the advantages of simple procedure, high yield and low processing cost, and is suitable for mass production.

The present invention relates to medicine technology and is improved mezlocillin sodium injection. The injection has one medicine weight ratio of mezlocillin sodium/Sulbactam sodium 1-16 to 1. It hasstrong antibacterial activity, wide antibacterial spectrum and thus high curative effect, and may be used in treating serious urinary tract infection, respiratory tract infection, intestinal tract, otorbinolaryngological infection, abdominal cavity infection, etc. caused by zymogenic staphylococcus, pneumococcus, enterococcus, purulent streptococcus, Hemophilus infuenzae, etc.

The invention discloses a preparation method of a mezlocillin sodium silica gel surface molecularly imprinted polymer, which comprises the following steps: activating silica gel by heating under reflux in hydrochloric acid, carrying out surface modification on the activated silica gel, and finally, synthesizing the mezlocillin sodium molecularly imprinted polymer on the silica gel surface. The mezlocillin sodium molecularly imprinted polymer is a porous structure, contains a structure complementary with template molecules inside, has a memory function, and thus, has very high specificity and selectivity for the template molecules.

The invention relates to a preparation process of Mezlocillin, which reacts Ampicillin trihydrate with 1-chlorocarbonyl-3-methylsulfonyl-2-imidazolidinone in water phase under alkaline condition and then proceeds acidified crystallization, filtration, washing and drying in acetone/water, or alcohol/water, or isopropanol/water system to obtain Mezlocillin. The Mezlocillin prepared by the inventive method can reach 95%-97% of molar yield, 0.06%-0.4% of organic residual quantity, more than 98.5% of dry basis content, less than 0.4% of single impurity, less than 1.5% of total related substances and good quality, is particularly suitable for direct lyophilization in water-phase salt formation to obtain high-quality Mezlocillin sodium for injection of medicinal product, and has prominent economical and social benefits.

The invention provided a method for preparing high-purity Mezlocillin sodium, and a method for preparing the Mezlocillin sodium powder injection. The method includes (1) dissolving Mezlocillin sodium crude product in purified water, and adjusting the pH value to less than 7 with the pH regulator; (2) extracting with organic solvent, separating the organic phase, drying with desiccant, and vacuum recovering to dry to obtain the product; (3) dissolving the product with eluting agent of mixed solution of hydrocarbon solvent and chlorine-containing solvent, eluting with alumina as filler of medium-pressure chromatography column, and collecting the fraction in a sectional manner; (4) mixing fractions with the Mezlocillin acid content of no smaller than 80%, vacuum concentrating, dissolving into ethanol, and basifying with base to separate precipitate; and (5) re-crystallizing the precipitate with ethanol, and freeze drying to obtain the high-purity Mezlocillin sodium.

The invention relates to a powder mixing technology for a compound antibiotic. The compound antibiotic is obtained by cold drying after uniform mixing of antibiotic A and antibiotic B in advance, wherein the antibiotic A is mezlocillin sodium, amoxicillin sodium, cefoperazone sodium, and piperacillin sodium, and the antibiotic B is sulbactam sodium. According to the powder mixing technology, organic solvent is omitted, the environment is less polluted, the freeze-drying technology has stable yield, and the cost is low; the freeze-drying mixed powder has good uniformity, fast dissolution rate, and stable chemical quality, so that the powder mixing technology is applicable to preparation of various of compound antibiotics, and is suitable for mass production.

The invention relates to the technical field of medicine and discloses injection mezlocillin sodium liposome and a preparation method. The injection mezlocillin sodium liposome is powder-injection. Mezlocillin sodium is packed with liposome carriers formed by liposome framework materials containing antioxygen and a stabilizing agent so as to obtain freezing-dried preparation. The injection mezlocillin sodium liposome is composed of 1 part of the mezlocillin sodium, 2 parts to 13 parts of the liposome framework materials, 0.3 part to 5 parts of the stabilizing agent, 4 parts to 10 parts of a freezing-dried protection agent and 0.1 part to 2 parts of the antioxygen. The injection mezlocillin sodium liposome has the obvious advantages that the mezlocillin sodium is wrapped in the liposome, thereby resolving the problem of slight solubility and guaranteeing quality of products; and medicine carrier liposome is degraded in bodies, thereby having no toxicity and immunogenicity, effectively improving therapeutic indexes of medicine, reducing toxicity of the medicine and reducing side effects of allergy rate, drug resistance, cardiotoxicity and the like.

The invention discloses a preparation method of mezlocillin sodium-sulbactam sodium for injection. The method comprises the following steps: firstly, adding mezlocillin into a mixing tank, and then dropwise adding a sodium hydrogen carbonate solution; after the addition is finished, adding sulbactam, and dropwise adding the sodium hydrogen carbonate solution again; after material feeding is finished, vacuumizing to remove carbon dioxide gas, and then adjusting the pH value to 6.0-6.5; then, adding an ethylene diamine tetraacetic acid (EDTA) solution, stirring for 15-30min, then vacuumizing again, and maintaining the pH value to be 6.0-6.5; sterilizing and filtering, and freeze-drying to obtain mezlocillin sodium-sulbactam sodium freeze-dried preparation raw powder for injection. Accordingto the method, mezlocillin sodium-sulbactam sodium is generated by using the mezlocillin, the sulbactam and sodium hydrogen carbonate as raw materials for carrying out a reaction, and the acidity stability of the product is improved by adding EDTA into reaction liquid, so that the mezlocillin sodium-sulbactam sodium, which has mezlocillin sodium content and sulbactam content meeting the requirements and is good in storage stability, for injection is finally obtained.

The invention relates to a mezlocillin sodium trihydrate, wherein the molecular formula thereof is C21H24N5NaO8S2.3H2O. The preparation method of the mezlocillin sodium trihydrate comprises the following steps: dissolving 5-10 parts of a mezlocillin sodium bulk drug with 10-20 parts of water according to parts by weight; placing the obtained dissolving solution into a crystallizer and then adding 60-90 parts of an elution agent by weight to cool to 2-8 DEG C; keeping a constant temperature for 2-5 hours; separating out a solid and then filtering to obtain the solid; and finally washing the solid with 3-5 parts of the elution agent, and then drying under a ventilating or vacuum condition for 3-5 hours at the temperature of 10-50 DEG C to obtain the mezlocillin sodium trihydrate. The invention further provides mezlocillin sodium for medicine injection which is prepared by crushing the mezlocillin sodium trihydrate, sieving the crushed mezlocillin sodium trihydrate with a 100 mesh sieve and then carrying out aseptic-packaging. The mezlocillin sodium trihydrate and the mezlocillin sodium for medicine injection which are obtained by the invention have clean surface, good product mobility, good stability and fast dissolution velocity.

The invention relates to a preparation technology of mezlocillin sodium, and belongs to the technical field of drug synthesis. The preparation technology comprises the steps of performing an acylation reaction on ampicillin trihydrate and 1-chloroformyl-3-mesyl-2-imidazolidinone under a low-temperature alkaline condition, performing decoloration, filtering, acidification, washing and dehydration, adding sodium salt, and then performing crystallization to obtain mezlocillin sodium, wherein ampicillin needs to be dissolved and clarified by triethylamine prior to the acylation reaction; and 1-chloroformyl-3-mesyl-2-imidazolidinone and an ethyl acetate solvent are mixed and then added to a reaction system twice. According to the preparation technology, a dissolution manner of ampicillin trihydrate is changed and an addition manner of 1-chloroformyl-3-mesyl-2-imidazolidinone is changed, so that a side reaction in a reaction process is reduced; the washing is performed by purified water after the acidification and anhydrous sodium acetate is used during the crystallization, so that impurities are further reduced; compared with an original drug, a prepared product has the advantages in the quantity and levels of the impurities.

The invention pertains to the technical field of drug combination preparation, more particularly relates to a preparation technique for mezlocillin. The preparation technique for mezlocillin comprises the following steps: ampicillin trihydrate and 1-chloroformyl-3-methylsulfonyl-2-imidazolidinone carry out acylation reaction under alkaline condition and then extraction, acidification and crystallization are conducted to obtain the mezlocillin. The invention is characterized in that when acylation reaction is conducted, reaction menstruum is water and acetone; after acylation reaction is finished, an ether extractant is added for carrying out extraction; and menthyl acetate is added before acidification so as to carry out acidified crystallization. The synthetic technique has obvious advantages, provides powerful guarantee for synthesizing the mezlocillin with high quality and has relatively great implementation value and long-term social and economic benefit.

The invention discloses a production process of mezlocillin sodium. The production process comprises the following steps: (1), cleaning, sterilizing and checking reaction equipment and a working place; (2), preparing a sodium bicarbonate suspension; (3), performing a salt forming reaction; (4), decoloring; (5), filtering and removing bacteria; (6), freeze-drying; (7), crushing; (8), packaging, wherein a salt forming reaction equation is described in the specification. According to the production process, in accordance with the provision of the new-edition Chinese pharmacopoeia, through improving a salt forming procedure and strictly controlling filtering, bacterium-removing, and freeze drying operations, the yield of drugs is increased; prepared mezlocillin sodium is low in content of polymer and impurities, and better in applicability and medicinal property.

The invention relates to the technical field of medicines and discloses a mezlocillin sodium and sulbactam sodium compound drug composition for injection. The mezlocillin sodium and sulbactam sodium compound drug composition comprises mezlocillin sodium, sulbactam sodium and sodium benzoate. The mezlocillin sodium and sulbactam sodium compound drug composition realizes higher product performance by less auxiliary materials, has the advantages of being good in solubility, shallow in color, uniform in main drug mixing, low in related substance, low in polymer content, low in incidence rate of adverse reactions and the like and ensures that patients are safer in the clinical use, and the treatment effect is more reliable.

The invention provides a detection method for determining polymer impurities in mezlocillin sodium. The detection method employs a high performance liquid chromatography size exclusion chromatography. The chromatography conditions are as follows: a chromatographic column employs hydrophilic silica for globular protein as a stationary phase and 50 mmol of a phosphate buffered solution as a mobile phase; a flow velocity of the mobile phase is 0.5-2.0 mL/min; a detection wavelength is 230-254 nm; a column temperature is a room temperature; a sample volume is 10-80 [mu]L; granularity of the chromatographic column stationary phase is 5 [mu]m, aperture of the chromatographic column stationary phase is 10 nm; the inner diameter of the chromatographic column is 7.8 mm; and the column length is 300 mm. he detection method can perform rapidly qualitative and quantitative determination on the polymer impurities in mezlocillin sodium, simultaneously simplifies operation steps, increases detection precision and shortens detection time.